The global ophthalmic drugs market is expected to reach USD 65.55 billion by 2030, garnering a CAGR of 7.80% from 2023 to 2030. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs. ![Global Ophthalmic Drugs Market]( "Global Ophthalmic Drugs Market")
According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.
Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics’ EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.
Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA’s HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.
Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.
According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.
Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics’ EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.
Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA’s HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.
Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.
Ophthalmic Drugs Market Report Highlights
- Anti-VEGF agents segment held the largest share in 2022 owing to their rising demand and lesser adverse effects
- Retinal disorders held the largest market share in 2022 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
- The topical route of administration dominated the market in 2022 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
- The eye drops segment is expected to hold the largest share in 2022 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
- Asia-Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Disease
1.2.3. Route of Administration
1.2.4. Dosage Type
1.2.5. Product Type
1.2.6. Product
1.2.7. Regional Scope
1.2.8. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.5.1. Data for Primary Interviews in North America
1.4.5.2. Data for Primary Interviews in Europe
1.4.5.3. Data for Primary Interviews in Asia-Pacific
1.4.5.4. Data for Primary Interviews in Latin America
1.4.5.5. Data for Primary Interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Disease
1.2.3. Route of Administration
1.2.4. Dosage Type
1.2.5. Product Type
1.2.6. Product
1.2.7. Regional Scope
1.2.8. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.5.1. Data for Primary Interviews in North America
1.4.5.2. Data for Primary Interviews in Europe
1.4.5.3. Data for Primary Interviews in Asia-Pacific
1.4.5.4. Data for Primary Interviews in Latin America
1.4.5.5. Data for Primary Interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class and disease outlook
2.2.2. Route of administration and dosage type outlook
2.2.3. Product type and product outlook
2.2.4. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Drug class and disease outlook
2.2.2. Route of administration and dosage type outlook
2.2.3. Product type and product outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing disease prevalence
3.2.1.2. Strong developmental pipeline
3.2.1.3. Advancement in drug delivery
3.2.1.4. Promising investment scenario
3.2.2. Market restraint analysis
3.2.2.1. Patent expiry of blockbuster drugs
3.3. Ophthalmic Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.5. Patent Expiry Analysis
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing disease prevalence
3.2.1.2. Strong developmental pipeline
3.2.1.3. Advancement in drug delivery
3.2.1.4. Promising investment scenario
3.2.2. Market restraint analysis
3.2.2.1. Patent expiry of blockbuster drugs
3.3. Ophthalmic Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.5. Patent Expiry Analysis
Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis
4.1. Drug Class Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Ophthalmic Drugs Market by Drug Class Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Anti-allergy
4.4.1.1. Anti-allergy market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Anti-VEGF Agents
4.4.2.1. Anti-VEGF agents market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3. Anti-inflammatory
4.4.3.1. Anti-inflammatory market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3.2. Non-steroidal drugs
4.4.3.2.1. Non-steroidal drugs market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3.3. Steroids
4.4.3.3.1. Steroids market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.4. Anti- glaucoma
4.4.4.1. Anti- glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5. Gene and Cell Therapy
4.4.5.1. Gene and cell therapy market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.6. Others
4.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
4.2. Segment Dashboard
4.3. Global Ophthalmic Drugs Market by Drug Class Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Anti-allergy
4.4.1.1. Anti-allergy market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Anti-VEGF Agents
4.4.2.1. Anti-VEGF agents market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3. Anti-inflammatory
4.4.3.1. Anti-inflammatory market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3.2. Non-steroidal drugs
4.4.3.2.1. Non-steroidal drugs market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3.3. Steroids
4.4.3.3.1. Steroids market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.4. Anti- glaucoma
4.4.4.1. Anti- glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5. Gene and Cell Therapy
4.4.5.1. Gene and cell therapy market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.6. Others
4.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis
5.1. Disease Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Ophthalmic Drugs Market by Disease Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Dry Eye
5.4.1.1. Dry eye market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.2. Allergies
5.4.2.1. Allergies market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.3. Glaucoma
5.4.3.1. Glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.4. Infection
5.4.4.1. Infection market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5. Retinal Disorders
5.4.5.1. Retinal disorders market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5.2. Macular Degeneration
5.4.5.2.1. Macular degeneration market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5.3. Diabetic Retinopathy
5.4.5.3.1. Diabetic retinopathy market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5.4. Others
5.4.5.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.6. Uveitis
5.4.6.1. Uveitis market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.7. Others
5.4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
5.2. Segment Dashboard
5.3. Global Ophthalmic Drugs Market by Disease Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Dry Eye
5.4.1.1. Dry eye market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.2. Allergies
5.4.2.1. Allergies market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.3. Glaucoma
5.4.3.1. Glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.4. Infection
5.4.4.1. Infection market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5. Retinal Disorders
5.4.5.1. Retinal disorders market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5.2. Macular Degeneration
5.4.5.2.1. Macular degeneration market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5.3. Diabetic Retinopathy
5.4.5.3.1. Diabetic retinopathy market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.5.4. Others
5.4.5.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.6. Uveitis
5.4.6.1. Uveitis market estimates and forecasts 2018 to 2030 (USD Billion)
5.4.7. Others
5.4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis
6.1. Route of Administration Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Ophthalmic Drugs Market by Route of Administration Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Topical
6.4.1.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Local Ocular
6.4.2.1. Local ocular market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.2. Subconjunctival
6.4.2.2.1. Subconjunctival market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.3. Intravitreal
6.4.2.3.1. Intravitreal market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.4. Retrobulbar
6.4.2.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.5. Intracameral
6.4.2.5.1. Intracameral market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.3. Systemic
6.4.3.1. Systemic market estimates and forecasts 2018 to 2030 (USD Billion)
6.2. Segment Dashboard
6.3. Global Ophthalmic Drugs Market by Route of Administration Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Topical
6.4.1.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2. Local Ocular
6.4.2.1. Local ocular market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.2. Subconjunctival
6.4.2.2.1. Subconjunctival market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.3. Intravitreal
6.4.2.3.1. Intravitreal market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.4. Retrobulbar
6.4.2.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.2.5. Intracameral
6.4.2.5.1. Intracameral market estimates and forecasts 2018 to 2030 (USD Billion)
6.4.3. Systemic
6.4.3.1. Systemic market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis
7.1. Dosage Type Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Ophthalmic Drugs Market by Dosage Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Gels
7.4.1.1. Gels market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.2. Eye Solutions and Suspensions
7.4.2.1. Eye solutions and suspensions market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.3. Capsules and Tablets
7.4.3.1. Capsules and tablets market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.4. Eye Drops
7.4.4.1. Eye drops market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.5. Ointments
7.4.5.1. Ointments market estimates and forecasts 2018 to 2030 (USD Billion)
7.2. Segment Dashboard
7.3. Global Ophthalmic Drugs Market by Dosage Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Gels
7.4.1.1. Gels market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.2. Eye Solutions and Suspensions
7.4.2.1. Eye solutions and suspensions market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.3. Capsules and Tablets
7.4.3.1. Capsules and tablets market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.4. Eye Drops
7.4.4.1. Eye drops market estimates and forecasts 2018 to 2030 (USD Billion)
7.4.5. Ointments
7.4.5.1. Ointments market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis
8.1. Product Type Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. Global Ophthalmic Drugs Market by Product Type Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. OTC
8.4.1.1. OTC market estimates and forecasts 2018 to 2030 (USD Billion)
8.4.2. Prescription Drugs
8.4.2.1. Prescription drugs market estimates and forecasts 2018 to 2030 (USD Billion)
8.2. Segment Dashboard
8.3. Global Ophthalmic Drugs Market by Product Type Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. OTC
8.4.1.1. OTC market estimates and forecasts 2018 to 2030 (USD Billion)
8.4.2. Prescription Drugs
8.4.2.1. Prescription drugs market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 9. Ophthalmic Drugs Market: Product Estimates & Trend Analysis
9.1. Product Market Share, 2023 & 2030
9.2. Segment Dashboard
9.3. Global Ophthalmic Drugs Market by Product Outlook
9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
9.4.1. Branded Drugs
9.4.1.1. Branded drugs market estimates and forecasts 2018 to 2030 (USD Billion)
9.4.2. Generic Drugs
9.4.2.1. Generic drugs market estimates and forecasts 2018 to 2030 (USD Billion)
9.2. Segment Dashboard
9.3. Global Ophthalmic Drugs Market by Product Outlook
9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
9.4.1. Branded Drugs
9.4.1.1. Branded drugs market estimates and forecasts 2018 to 2030 (USD Billion)
9.4.2. Generic Drugs
9.4.2.1. Generic drugs market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis
10.1. Regional Market Share Analysis, 2023 & 2030
10.2. Regional Market Dashboard
10.3. Global Regional Market Snapshot
10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
10.5. North America
10.5.1. U.S.
10.5.1.1. Key country dynamics
10.5.1.2. Regulatory framework/ reimbursement structure
10.5.1.3. Competitive scenario
10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
10.5.2. Canada
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework/ reimbursement structure
10.5.2.3. Competitive scenario
10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
10.6. Europe
10.6.1. UK
10.6.1.1. Key country dynamics
10.6.1.2. Regulatory framework/ reimbursement structure
10.6.1.3. Competitive scenario
10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.2. Germany
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework/ reimbursement structure
10.6.2.3. Competitive scenario
10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.3. France
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework/ reimbursement structure
10.6.3.3. Competitive scenario
10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.4. Italy
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework/ reimbursement structure
10.6.4.3. Competitive scenario
10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.5. Spain
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework/ reimbursement structure
10.6.5.3. Competitive scenario
10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.6. Norway
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework/ reimbursement structure
10.6.6.3. Competitive scenario
10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.7. Sweden
10.6.7.1. Key country dynamics
10.6.7.2. Regulatory framework/ reimbursement structure
10.6.7.3. Competitive scenario
10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.8. Denmark
10.6.8.1. Key country dynamics
10.6.8.2. Regulatory framework/ reimbursement structure
10.6.8.3. Competitive scenario
10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
10.7. Asia-Pacific
10.7.1. Japan
10.7.1.1. Key country dynamics
10.7.1.2. Regulatory framework/ reimbursement structure
10.7.1.3. Competitive scenario
10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.2. China
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework/ reimbursement structure
10.7.2.3. Competitive scenario
10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.3. India
10.7.3.1. Key country dynamics
10.7.3.2. Regulatory framework/ reimbursement structure
10.7.3.3. Competitive scenario
10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.4. Australia
10.7.4.1. Key country dynamics
10.7.4.2. Regulatory framework/ reimbursement structure
10.7.4.3. Competitive scenario
10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.5. South Korea
10.7.5.1. Key country dynamics
10.7.5.2. Regulatory framework/ reimbursement structure
10.7.5.3. Competitive scenario
10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.6. Thailand
10.7.6.1. Key country dynamics
10.7.6.2. Regulatory framework/ reimbursement structure
10.7.6.3. Competitive scenario
10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
10.8. Latin America
10.8.1. Brazil
10.8.1.1. Key country dynamics
10.8.1.2. Regulatory framework/ reimbursement structure
10.8.1.3. Competitive scenario
10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
10.8.2. Mexico
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework/ reimbursement structure
10.8.2.3. Competitive scenario
10.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
10.8.3. Argentina
10.8.3.1. Key country dynamics
10.8.3.2. Regulatory framework/ reimbursement structure
10.8.3.3. Competitive scenario
10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
10.9. MEA
10.9.1. South Africa
10.9.1.1. Key country dynamics
10.9.1.2. Regulatory framework/ reimbursement structure
10.9.1.3. Competitive scenario
10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
10.9.2. Saudi Arabia
10.9.2.1. Key country dynamics
10.9.2.2. Regulatory framework/ reimbursement structure
10.9.2.3. Competitive scenario
10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
10.9.3. UAE
10.9.3.1. Key country dynamics
10.9.3.2. Regulatory framework/ reimbursement structure
10.9.3.3. Competitive scenario
10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
10.9.4. Kuwait
10.9.4.1. Key country dynamics
10.9.4.2. Regulatory framework/ reimbursement structure
10.9.4.3. Competitive scenario
10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
10.2. Regional Market Dashboard
10.3. Global Regional Market Snapshot
10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
10.5. North America
10.5.1. U.S.
10.5.1.1. Key country dynamics
10.5.1.2. Regulatory framework/ reimbursement structure
10.5.1.3. Competitive scenario
10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
10.5.2. Canada
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework/ reimbursement structure
10.5.2.3. Competitive scenario
10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
10.6. Europe
10.6.1. UK
10.6.1.1. Key country dynamics
10.6.1.2. Regulatory framework/ reimbursement structure
10.6.1.3. Competitive scenario
10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.2. Germany
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework/ reimbursement structure
10.6.2.3. Competitive scenario
10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.3. France
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework/ reimbursement structure
10.6.3.3. Competitive scenario
10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.4. Italy
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework/ reimbursement structure
10.6.4.3. Competitive scenario
10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.5. Spain
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework/ reimbursement structure
10.6.5.3. Competitive scenario
10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.6. Norway
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework/ reimbursement structure
10.6.6.3. Competitive scenario
10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.7. Sweden
10.6.7.1. Key country dynamics
10.6.7.2. Regulatory framework/ reimbursement structure
10.6.7.3. Competitive scenario
10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
10.6.8. Denmark
10.6.8.1. Key country dynamics
10.6.8.2. Regulatory framework/ reimbursement structure
10.6.8.3. Competitive scenario
10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
10.7. Asia-Pacific
10.7.1. Japan
10.7.1.1. Key country dynamics
10.7.1.2. Regulatory framework/ reimbursement structure
10.7.1.3. Competitive scenario
10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.2. China
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework/ reimbursement structure
10.7.2.3. Competitive scenario
10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.3. India
10.7.3.1. Key country dynamics
10.7.3.2. Regulatory framework/ reimbursement structure
10.7.3.3. Competitive scenario
10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.4. Australia
10.7.4.1. Key country dynamics
10.7.4.2. Regulatory framework/ reimbursement structure
10.7.4.3. Competitive scenario
10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.5. South Korea
10.7.5.1. Key country dynamics
10.7.5.2. Regulatory framework/ reimbursement structure
10.7.5.3. Competitive scenario
10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
10.7.6. Thailand
10.7.6.1. Key country dynamics
10.7.6.2. Regulatory framework/ reimbursement structure
10.7.6.3. Competitive scenario
10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
10.8. Latin America
10.8.1. Brazil
10.8.1.1. Key country dynamics
10.8.1.2. Regulatory framework/ reimbursement structure
10.8.1.3. Competitive scenario
10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
10.8.2. Mexico
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework/ reimbursement structure
10.8.2.3. Competitive scenario
10.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
10.8.3. Argentina
10.8.3.1. Key country dynamics
10.8.3.2. Regulatory framework/ reimbursement structure
10.8.3.3. Competitive scenario
10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
10.9. MEA
10.9.1. South Africa
10.9.1.1. Key country dynamics
10.9.1.2. Regulatory framework/ reimbursement structure
10.9.1.3. Competitive scenario
10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
10.9.2. Saudi Arabia
10.9.2.1. Key country dynamics
10.9.2.2. Regulatory framework/ reimbursement structure
10.9.2.3. Competitive scenario
10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
10.9.3. UAE
10.9.3.1. Key country dynamics
10.9.3.2. Regulatory framework/ reimbursement structure
10.9.3.3. Competitive scenario
10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
10.9.4. Kuwait
10.9.4.1. Key country dynamics
10.9.4.2. Regulatory framework/ reimbursement structure
10.9.4.3. Competitive scenario
10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 11. Competitive Landscape
11.1. Recent Developments & Impact Analysis, by Key Market Participants
11.2. Company/Competition Categorization
11.3. Vendor Landscape
11.3.1. List of key distributors and channel partners
11.3.2. Key customers
11.3.3. Key company market share analysis, 2023
11.3.4. Pfizer Inc.
11.3.4.1. Company overview
11.3.4.2. Financial performance
11.3.4.3. Product benchmarking
11.3.4.4. Strategic initiatives
11.3.5. Alcon
11.3.5.1. Company overview
11.3.5.2. Financial performance
11.3.5.3. Product benchmarking
11.3.5.4. Strategic initiatives
11.3.6. Novartis AG
11.3.6.1. Company overview
11.3.6.2. Financial performance
11.3.6.3. Product benchmarking
11.3.6.4. Strategic initiatives
11.3.7. Bausch Health Companies Inc.
11.3.7.1. Company overview
11.3.7.2. Financial performance
11.3.7.3. Product benchmarking
11.3.7.4. Strategic initiatives
11.3.8. Merck & Co., Inc.
11.3.8.1. Company overview
11.3.8.2. Financial performance
11.3.8.3. Product benchmarking
11.3.8.4. Strategic initiatives
11.3.9. Regeneron Pharmaceuticals Inc.
11.3.9.1. Company overview
11.3.9.2. Financial performance
11.3.9.3. Product benchmarking
11.3.9.4. Strategic initiatives
11.3.10. Allergan (AbbVie Inc)
11.3.10.1. Company overview
11.3.10.2. Financial performance
11.3.10.3. Product benchmarking
11.3.10.4. Strategic initiatives
11.3.11. Bayer AG
11.3.11.1. Company overview
11.3.11.2. Financial performance
11.3.11.3. Product benchmarking
11.3.11.4. Strategic initiatives
11.3.12. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
11.3.12.1. Company overview
11.3.12.2. Financial performance
11.3.12.3. Product benchmarking
11.3.12.4. Strategic initiatives
11.3.13. Nicox
11.3.13.1. Company overview
11.3.13.2. Financial performance
11.3.13.3. Product benchmarking
11.3.13.4. Strategic initiatives
11.3.14. Coherus BioSciences
11.3.14.1. Company overview
11.3.14.2. Financial performance
11.3.14.3. Product benchmarking
11.3.14.4. Strategic initiatives
11.2. Company/Competition Categorization
11.3. Vendor Landscape
11.3.1. List of key distributors and channel partners
11.3.2. Key customers
11.3.3. Key company market share analysis, 2023
11.3.4. Pfizer Inc.
11.3.4.1. Company overview
11.3.4.2. Financial performance
11.3.4.3. Product benchmarking
11.3.4.4. Strategic initiatives
11.3.5. Alcon
11.3.5.1. Company overview
11.3.5.2. Financial performance
11.3.5.3. Product benchmarking
11.3.5.4. Strategic initiatives
11.3.6. Novartis AG
11.3.6.1. Company overview
11.3.6.2. Financial performance
11.3.6.3. Product benchmarking
11.3.6.4. Strategic initiatives
11.3.7. Bausch Health Companies Inc.
11.3.7.1. Company overview
11.3.7.2. Financial performance
11.3.7.3. Product benchmarking
11.3.7.4. Strategic initiatives
11.3.8. Merck & Co., Inc.
11.3.8.1. Company overview
11.3.8.2. Financial performance
11.3.8.3. Product benchmarking
11.3.8.4. Strategic initiatives
11.3.9. Regeneron Pharmaceuticals Inc.
11.3.9.1. Company overview
11.3.9.2. Financial performance
11.3.9.3. Product benchmarking
11.3.9.4. Strategic initiatives
11.3.10. Allergan (AbbVie Inc)
11.3.10.1. Company overview
11.3.10.2. Financial performance
11.3.10.3. Product benchmarking
11.3.10.4. Strategic initiatives
11.3.11. Bayer AG
11.3.11.1. Company overview
11.3.11.2. Financial performance
11.3.11.3. Product benchmarking
11.3.11.4. Strategic initiatives
11.3.12. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
11.3.12.1. Company overview
11.3.12.2. Financial performance
11.3.12.3. Product benchmarking
11.3.12.4. Strategic initiatives
11.3.13. Nicox
11.3.13.1. Company overview
11.3.13.2. Financial performance
11.3.13.3. Product benchmarking
11.3.13.4. Strategic initiatives
11.3.14. Coherus BioSciences
11.3.14.1. Company overview
11.3.14.2. Financial performance
11.3.14.3. Product benchmarking
11.3.14.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 3 North America ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 4 North America ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 5 North America ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 6 North America ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 7 North America ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 8 North America ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 9 U.S. ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 10 U.S. ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 11 U.S. ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 12 U.S. ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 13 U.S. ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 14 U.S. ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 15 Canada ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 16 Canada ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 17 Canada ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 18 Canada ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 19 Canada ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 20 Canada ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 21 Europe ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 22 Europe ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 23 Europe ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 24 Europe ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 25 Europe ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 26 Europe ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 27 Europe ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 28 Germany ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 29 Germany ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 30 Germany ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 31 Germany ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 32 Germany ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 33 Germany ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 34 UK ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 35 UK ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 36 UK ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 37 UK ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 38 UK ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 39 UK ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 40 France ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 41 France ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 42 France ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 43 France ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 44 France ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 45 France ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 46 Italy ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 47 Italy ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 48 Italy ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 49 Italy ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 50 Italy ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 51 Italy ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 52 Spain ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 53 Spain ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 54 Spain ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 55 Spain ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 56 Spain ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 57 Spain ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 58 Denmark ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 59 Denmark ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 60 Denmark ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 61 Denmark ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 62 Denmark ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 63 Denmark ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 64 Sweden ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 65 Sweden ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 66 Sweden ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 67 Sweden ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 68 Sweden ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 69 Sweden ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 70 Norway ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 71 Norway ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 72 Norway ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 73 Norway ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 74 Norway ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 75 Norway ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 76 Asia-Pacific ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 77 Asia-Pacific ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 78 Asia-Pacific ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 79 Aisa Pacific ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 80 Aisa Pacific ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 81 Aisa Pacific ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 82 Aisa Pacific ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 83 China ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 84 China ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 85 China ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 86 China ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 87 China ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 88 China ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 89 Japan ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 90 Japan ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 91 Japan ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 92 Japan ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 93 Japan ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 94 Japan ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 95 India ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 96 India ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 97 India ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 98 India ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 99 India ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 100 India ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 101 South Korea ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 102 South Korea ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 103 South Korea ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 104 South Korea ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 105 South Korea ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 106 South Korea ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 107 Australia ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 108 Australia ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 109 Australia ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 110 Australia ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 111 Australia ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 112 Australia ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 113 Thailand ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 114 Thailand ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 115 Thailand ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 116 Thailand ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 117 Thailand ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 118 Thailand ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 119 Latin America ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 120 Latin America ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 121 Latin America ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 122 Latin America ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 123 Latin America ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 124 Latin America ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 125 Latin America ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 126 Brazil ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 127 Brazil ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 128 Brazil ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 129 Brazil ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 130 Brazil ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 131 Brazil ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 132 Mexico ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 133 Mexico ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 134 Mexico ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 135 Mexico ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 136 Mexico ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 137 Mexico ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 138 Argentina ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 139 Argentina ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 140 Argentina ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 141 Argentina ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 142 Argentina ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 143 Argentina ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 144 MEA ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 145 MEA ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 146 MEA ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 147 MEA ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 148 MEA ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 149 MEA ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 150 MEA ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 151 South Africa ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 152 South Africa ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 153 South Africa ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 154 South Africa ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 155 South Africa ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 156 South Africa ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 157 Saudi Arabia ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 158 Saudi Arabia ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 159 Saudi Arabia ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 160 Saudi Arabia ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 161 Saudi Arabia ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 162 Saudi Arabia ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 163 UAE ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 164 UAE ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 165 UAE ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 166 UAE ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 167 UAE ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 168 UAE ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 169 Kuwait ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 170 Kuwait ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 171 Kuwait ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 172 Kuwait ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 173 Kuwait ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 174 Kuwait ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 2 North America ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 3 North America ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 4 North America ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 5 North America ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 6 North America ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 7 North America ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 8 North America ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 9 U.S. ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 10 U.S. ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 11 U.S. ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 12 U.S. ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 13 U.S. ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 14 U.S. ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 15 Canada ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 16 Canada ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 17 Canada ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 18 Canada ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 19 Canada ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 20 Canada ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 21 Europe ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 22 Europe ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 23 Europe ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 24 Europe ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 25 Europe ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 26 Europe ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 27 Europe ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 28 Germany ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 29 Germany ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 30 Germany ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 31 Germany ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 32 Germany ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 33 Germany ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 34 UK ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 35 UK ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 36 UK ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 37 UK ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 38 UK ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 39 UK ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 40 France ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 41 France ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 42 France ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 43 France ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 44 France ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 45 France ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 46 Italy ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 47 Italy ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 48 Italy ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 49 Italy ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 50 Italy ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 51 Italy ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 52 Spain ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 53 Spain ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 54 Spain ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 55 Spain ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 56 Spain ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 57 Spain ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 58 Denmark ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 59 Denmark ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 60 Denmark ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 61 Denmark ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 62 Denmark ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 63 Denmark ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 64 Sweden ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 65 Sweden ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 66 Sweden ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 67 Sweden ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 68 Sweden ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 69 Sweden ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 70 Norway ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 71 Norway ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 72 Norway ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 73 Norway ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 74 Norway ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 75 Norway ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 76 Asia-Pacific ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 77 Asia-Pacific ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 78 Asia-Pacific ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 79 Aisa Pacific ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 80 Aisa Pacific ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 81 Aisa Pacific ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 82 Aisa Pacific ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 83 China ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 84 China ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 85 China ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 86 China ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 87 China ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 88 China ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 89 Japan ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 90 Japan ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 91 Japan ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 92 Japan ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 93 Japan ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 94 Japan ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 95 India ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 96 India ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 97 India ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 98 India ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 99 India ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 100 India ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 101 South Korea ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 102 South Korea ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 103 South Korea ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 104 South Korea ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 105 South Korea ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 106 South Korea ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 107 Australia ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 108 Australia ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 109 Australia ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 110 Australia ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 111 Australia ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 112 Australia ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 113 Thailand ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 114 Thailand ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 115 Thailand ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 116 Thailand ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 117 Thailand ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 118 Thailand ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 119 Latin America ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 120 Latin America ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 121 Latin America ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 122 Latin America ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 123 Latin America ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 124 Latin America ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 125 Latin America ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 126 Brazil ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 127 Brazil ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 128 Brazil ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 129 Brazil ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 130 Brazil ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 131 Brazil ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 132 Mexico ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 133 Mexico ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 134 Mexico ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 135 Mexico ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 136 Mexico ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 137 Mexico ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 138 Argentina ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 139 Argentina ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 140 Argentina ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 141 Argentina ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 142 Argentina ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 143 Argentina ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 144 MEA ophthalmic drugs market, by region 2018-2030 (USD Billion)
Table 145 MEA ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 146 MEA ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 147 MEA ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 148 MEA ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 149 MEA ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 150 MEA ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 151 South Africa ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 152 South Africa ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 153 South Africa ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 154 South Africa ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 155 South Africa ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 156 South Africa ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 157 Saudi Arabia ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 158 Saudi Arabia ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 159 Saudi Arabia ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 160 Saudi Arabia ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 161 Saudi Arabia ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 162 Saudi Arabia ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 163 UAE ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 164 UAE ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 165 UAE ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 166 UAE ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 167 UAE ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 168 UAE ophthalmic drugs market, by product 2018-2030 (USD Billion)
Table 169 Kuwait ophthalmic drugs market, by drug class 2018-2030 (USD Billion)
Table 170 Kuwait ophthalmic drugs market, by disease 2018-2030 (USD Billion)
Table 171 Kuwait ophthalmic drugs market, by route of administration 2018-2030 (USD Billion)
Table 172 Kuwait ophthalmic drugs market, by dosage type 2018-2030 (USD Billion)
Table 173 Kuwait ophthalmic drugs market, by product type 2018-2030 (USD Billion)
Table 174 Kuwait ophthalmic drugs market, by product 2018-2030 (USD Billion)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Ophthalmic drugs market: market outlook
Fig. 14 Tumor ablation competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Ophthalmic drugs market driver impact
Fig. 20 Ophthalmic drugs market restraint impact
Fig. 21 Ophthalmic drugs market strategic initiatives analysis
Fig. 22 Ophthalmic drugs market: Drug class movement analysis
Fig. 23 Ophthalmic drugs market: Drug class outlook and key takeaways
Fig. 24 Anti-allergy market estimates and forecast, 2018-2030
Fig. 25 Anti-VEGF agents estimates and forecast, 2018-2030
Fig. 26 Anti-inflammatory market estimates and forecast, 2018-2030
Fig. 27 Anti-glaucoma estimates and forecast, 2018-2030
Fig. 28 Gene and cell therapy market estimates and forecast, 2018-2030
Fig. 29 Others estimates and forecast, 2018-2030
Fig. 30 Ophthalmic drugs market: Disease movement analysis
Fig. 31 Ophthalmic drugs market: Disease outlook and key takeaways
Fig. 32 Dry eye market estimates and forecast, 2018-2030
Fig. 33 Allergies estimates and forecast, 2018-2030
Fig. 34 Glaucoma market estimates and forecast, 2018-2030
Fig. 35 Infection estimates and forecast, 2018-2030
Fig. 36 Retinal disorders market estimates and forecast, 2018-2030
Fig. 37 Uveitis estimates and forecast, 2018-2030
Fig. 38 Others estimates and forecast, 2018-2030
Fig. 39 Ophthalmic drugs market: Route of administration movement analysis
Fig. 40 Ophthalmic drugs market: Route of administration outlook and key takeaways
Fig. 41 Topical market estimates and forecast, 2018-2030
Fig. 42 Local ocular estimates and forecast, 2018-2030
Fig. 43 Systemic market estimates and forecast, 2018-2030
Fig. 44 Ophthalmic drugs market: Dosage type movement analysis
Fig. 45 Ophthalmic drugs market: Dosage type outlook and key takeaways
Fig. 46 Gels market estimates and forecast, 2018-2030
Fig. 47 Eye solutions and suspensions estimates and forecast, 2018-2030
Fig. 48 Capsules and tablets market estimates and forecast, 2018-2030
Fig. 49 Eye drops estimates and forecast, 2018-2030
Fig. 50 Ointments market estimates and forecast, 2018-2030
Fig. 51 Ophthalmic drugs market: Product type movement analysis
Fig. 52 Ophthalmic drugs market: Product type outlook and key takeaways
Fig. 53 OTC market estimates and forecast, 2018-2030
Fig. 54 Prescription drugs estimates and forecast, 2018-2030
Fig. 55 Ophthalmic drugs market: Product movement Analysis
Fig. 56 Ophthalmic drugs market: Product outlook and key takeaways
Fig. 57 Branded drugs market estimates and forecasts, 2018-2030
Fig. 58 Generic drugs market estimates and forecasts,2018-2030
Fig. 59 Global ophthalmic drugs market: Regional movement analysis
Fig. 60 Global ophthalmic drugs market: Regional outlook and key takeaways
Fig. 61 Global ophthalmic drugs market share and leading players
Fig. 62 North America market share and leading players
Fig. 63 Europe market share and leading players
Fig. 64 Asia-Pacific market share and leading players
Fig. 65 Latin America market share and leading players
Fig. 66 Middle East & Africa market share and leading players
Fig. 67 North America: SWOT
Fig. 68 Europe SWOT
Fig. 69 Asia-Pacific SWOT
Fig. 70 Latin America SWOT
Fig. 71 MEA SWOT
Fig. 72 North America, by country
Fig. 73 North America
Fig. 74 North America market estimates and forecasts, 2018-2030
Fig. 75 U.S. key country dynamics
Fig. 76 U.S. market estimates and forecasts, 2018-2030
Fig. 77 Canada key country dynamics
Fig. 78 Canada market estimates and forecasts, 2018-2030
Fig. 79 Europe
Fig. 80 Europe market estimates and forecasts, 2018-2030
Fig. 81 UK key country dynamics
Fig. 82 UK market estimates and forecasts, 2018-2030
Fig. 83 Germany key country dynamics
Fig. 84 Germany market estimates and forecasts, 2018-2030
Fig. 85 France key country dynamics
Fig. 86 France market estimates and forecasts, 2018-2030
Fig. 87 Italy key country dynamics
Fig. 88 Italy market estimates and forecasts, 2018-2030
Fig. 89 Spain key country dynamics
Fig. 90 Spain market estimates and forecasts, 2018-2030
Fig. 91 Denmark key country dynamics
Fig. 92 Denmark market estimates and forecasts, 2018-2030
Fig. 93 Sweden key country dynamics
Fig. 94 Sweden market estimates and forecasts, 2018-2030
Fig. 95 Norway key country dynamics
Fig. 96 Norway market estimates and forecasts, 2018-2030
Fig. 97 Asia-Pacific
Fig. 98 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 99 China key country dynamics
Fig. 100 China market estimates and forecasts, 2018-2030
Fig. 101 Japan key country dynamics
Fig. 102 Japan market estimates and forecasts, 2018-2030
Fig. 103 India key country dynamics
Fig. 104 India market estimates and forecasts, 2018-2030
Fig. 105 Thailand key country dynamics
Fig. 106 Thailand market estimates and forecasts, 2018-2030
Fig. 107 South Korea key country dynamics
Fig. 108 South Korea market estimates and forecasts, 2018-2030
Fig. 109 Australia key country dynamics
Fig. 110 Australia market estimates and forecasts, 2018-2030
Fig. 111 Latin America
Fig. 112 Latin America market estimates and forecasts, 2018-2030
Fig. 113 Brazil key country dynamics
Fig. 114 Brazil market estimates and forecasts, 2018-2030
Fig. 115 Mexico key country dynamics
Fig. 116 Mexico market estimates and forecasts, 2018-2030
Fig. 117 Argentina key country dynamics
Fig. 118 Argentina market estimates and forecasts, 2018-2030
Fig. 119 Middle East and Africa
Fig. 120 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 121 South Africa key country dynamics
Fig. 122 South Africa market estimates and forecasts, 2018-2030
Fig. 123 Saudi Arabia key country dynamics
Fig. 124 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 125 UAE key country dynamics
Fig. 126 UAE market estimates and forecasts, 2018-2030
Fig. 127 Kuwait key country dynamics
Fig. 128 Kuwait market estimates and forecasts, 2018-2030
Fig. 129 Market share of key market players- Ophthalmic drugs market
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Ophthalmic drugs market: market outlook
Fig. 14 Tumor ablation competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Ophthalmic drugs market driver impact
Fig. 20 Ophthalmic drugs market restraint impact
Fig. 21 Ophthalmic drugs market strategic initiatives analysis
Fig. 22 Ophthalmic drugs market: Drug class movement analysis
Fig. 23 Ophthalmic drugs market: Drug class outlook and key takeaways
Fig. 24 Anti-allergy market estimates and forecast, 2018-2030
Fig. 25 Anti-VEGF agents estimates and forecast, 2018-2030
Fig. 26 Anti-inflammatory market estimates and forecast, 2018-2030
Fig. 27 Anti-glaucoma estimates and forecast, 2018-2030
Fig. 28 Gene and cell therapy market estimates and forecast, 2018-2030
Fig. 29 Others estimates and forecast, 2018-2030
Fig. 30 Ophthalmic drugs market: Disease movement analysis
Fig. 31 Ophthalmic drugs market: Disease outlook and key takeaways
Fig. 32 Dry eye market estimates and forecast, 2018-2030
Fig. 33 Allergies estimates and forecast, 2018-2030
Fig. 34 Glaucoma market estimates and forecast, 2018-2030
Fig. 35 Infection estimates and forecast, 2018-2030
Fig. 36 Retinal disorders market estimates and forecast, 2018-2030
Fig. 37 Uveitis estimates and forecast, 2018-2030
Fig. 38 Others estimates and forecast, 2018-2030
Fig. 39 Ophthalmic drugs market: Route of administration movement analysis
Fig. 40 Ophthalmic drugs market: Route of administration outlook and key takeaways
Fig. 41 Topical market estimates and forecast, 2018-2030
Fig. 42 Local ocular estimates and forecast, 2018-2030
Fig. 43 Systemic market estimates and forecast, 2018-2030
Fig. 44 Ophthalmic drugs market: Dosage type movement analysis
Fig. 45 Ophthalmic drugs market: Dosage type outlook and key takeaways
Fig. 46 Gels market estimates and forecast, 2018-2030
Fig. 47 Eye solutions and suspensions estimates and forecast, 2018-2030
Fig. 48 Capsules and tablets market estimates and forecast, 2018-2030
Fig. 49 Eye drops estimates and forecast, 2018-2030
Fig. 50 Ointments market estimates and forecast, 2018-2030
Fig. 51 Ophthalmic drugs market: Product type movement analysis
Fig. 52 Ophthalmic drugs market: Product type outlook and key takeaways
Fig. 53 OTC market estimates and forecast, 2018-2030
Fig. 54 Prescription drugs estimates and forecast, 2018-2030
Fig. 55 Ophthalmic drugs market: Product movement Analysis
Fig. 56 Ophthalmic drugs market: Product outlook and key takeaways
Fig. 57 Branded drugs market estimates and forecasts, 2018-2030
Fig. 58 Generic drugs market estimates and forecasts,2018-2030
Fig. 59 Global ophthalmic drugs market: Regional movement analysis
Fig. 60 Global ophthalmic drugs market: Regional outlook and key takeaways
Fig. 61 Global ophthalmic drugs market share and leading players
Fig. 62 North America market share and leading players
Fig. 63 Europe market share and leading players
Fig. 64 Asia-Pacific market share and leading players
Fig. 65 Latin America market share and leading players
Fig. 66 Middle East & Africa market share and leading players
Fig. 67 North America: SWOT
Fig. 68 Europe SWOT
Fig. 69 Asia-Pacific SWOT
Fig. 70 Latin America SWOT
Fig. 71 MEA SWOT
Fig. 72 North America, by country
Fig. 73 North America
Fig. 74 North America market estimates and forecasts, 2018-2030
Fig. 75 U.S. key country dynamics
Fig. 76 U.S. market estimates and forecasts, 2018-2030
Fig. 77 Canada key country dynamics
Fig. 78 Canada market estimates and forecasts, 2018-2030
Fig. 79 Europe
Fig. 80 Europe market estimates and forecasts, 2018-2030
Fig. 81 UK key country dynamics
Fig. 82 UK market estimates and forecasts, 2018-2030
Fig. 83 Germany key country dynamics
Fig. 84 Germany market estimates and forecasts, 2018-2030
Fig. 85 France key country dynamics
Fig. 86 France market estimates and forecasts, 2018-2030
Fig. 87 Italy key country dynamics
Fig. 88 Italy market estimates and forecasts, 2018-2030
Fig. 89 Spain key country dynamics
Fig. 90 Spain market estimates and forecasts, 2018-2030
Fig. 91 Denmark key country dynamics
Fig. 92 Denmark market estimates and forecasts, 2018-2030
Fig. 93 Sweden key country dynamics
Fig. 94 Sweden market estimates and forecasts, 2018-2030
Fig. 95 Norway key country dynamics
Fig. 96 Norway market estimates and forecasts, 2018-2030
Fig. 97 Asia-Pacific
Fig. 98 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 99 China key country dynamics
Fig. 100 China market estimates and forecasts, 2018-2030
Fig. 101 Japan key country dynamics
Fig. 102 Japan market estimates and forecasts, 2018-2030
Fig. 103 India key country dynamics
Fig. 104 India market estimates and forecasts, 2018-2030
Fig. 105 Thailand key country dynamics
Fig. 106 Thailand market estimates and forecasts, 2018-2030
Fig. 107 South Korea key country dynamics
Fig. 108 South Korea market estimates and forecasts, 2018-2030
Fig. 109 Australia key country dynamics
Fig. 110 Australia market estimates and forecasts, 2018-2030
Fig. 111 Latin America
Fig. 112 Latin America market estimates and forecasts, 2018-2030
Fig. 113 Brazil key country dynamics
Fig. 114 Brazil market estimates and forecasts, 2018-2030
Fig. 115 Mexico key country dynamics
Fig. 116 Mexico market estimates and forecasts, 2018-2030
Fig. 117 Argentina key country dynamics
Fig. 118 Argentina market estimates and forecasts, 2018-2030
Fig. 119 Middle East and Africa
Fig. 120 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 121 South Africa key country dynamics
Fig. 122 South Africa market estimates and forecasts, 2018-2030
Fig. 123 Saudi Arabia key country dynamics
Fig. 124 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 125 UAE key country dynamics
Fig. 126 UAE market estimates and forecasts, 2018-2030
Fig. 127 Kuwait key country dynamics
Fig. 128 Kuwait market estimates and forecasts, 2018-2030
Fig. 129 Market share of key market players- Ophthalmic drugs market
Companies Mentioned
- Pfizer Inc.
- Alcon
- Novartis AG
- Bausch Health Companies Inc.
- Merck & Co., Inc.
- Regeneron Pharmaceuticals Inc.
- Allergan (AbbVie Inc)
- Bayer AG
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- Nicox
- Coherus BioSciences
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | January 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 37.82 Billion |
| Forecasted Market Value ( USD | $ 65.55 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
